SCHEMBL17447307

SCHEMBL17447307

Fc1cc2[nH]ncc2cc1CNCl

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KLKB1 P03952 1/20 0.41
MAP4K1 Q92918 1/20 0.41
CHEK1 O14757 1/20 0.41
TRPA1 O75762 2/20 0.40
NOS1 P29475 2/20 0.39
DYRK1A Q13627 1/20 0.39
FGFR1 P11362 2/20 0.38
FGFR2 P21802 2/20 0.38
MKNK1 Q9BUB5 1/20 0.38
CTNNB1 P35222 2/20 0.38
WNT3A P56704 2/20 0.38
ROCK2 O75116 2/20 0.37
ROCK1 Q13464 2/20 0.37
MAPK1 P28482 1/20 0.37
CYP1A2 P05177 1/20 0.36
CYP3A4 P08684 1/20 0.36
CYP2D6 P10635 1/20 0.36
CYP2C9 P11712 1/20 0.36
CYP2C19 P33261 1/20 0.36
TGFBR1 P36897 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17920385 0.78 CHEK1 (0.48) CHEK1TRPA1NOS1DYRK1AFGFR1
SCHEMBL7918116 0.78 TRPA1 (0.49) CHEK1TRPA1NOS1FGFR1FGFR2
Hydrochloric Acid SCHEMBL17442720 0.77 CHEK1 (0.47) CHEK1TRPA1NOS1DYRK1AFGFR1
SCHEMBL14738406 0.74 CHEK1 (0.56) CHEK1TRPA1NOS1DYRK1AFGFR1
SCHEMBL27604935 0.73 CTNNB1 (0.43) KLKB1MAP4K1CHEK1TRPA1FGFR1
SCHEMBL23977642 0.72 NOS1 (0.50) CHEK1TRPA1NOS1DYRK1AFGFR1
SCHEMBL27445825 0.71 TRPA1 (0.52) CHEK1TRPA1FGFR1FGFR2CTNNB1
SCHEMBL24337912 0.71 CHEK1 (0.44) CHEK1TRPA1NOS1DYRK1AFGFR1
SCHEMBL10210705 0.70 MAPK1 (0.62) NOS1DYRK1AROCK2ROCK1MAPK1
SCHEMBL10210529 0.70 INSR (0.54) NOS1DYRK1AFGFR1FGFR2MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170260163-A1 THERAPEUTIC INHIBITORY COMPOUNDS ATTUNE PHARMACEUTICALS, INC. 2017-09-14 US disclosed
US-9611252-B2 Therapeutic inhibitory compounds LIFESCI PHARMACEUTICALS, INC. (BB) 2017-04-04 US disclosed
US-20170029406-A1 THERAPEUTIC INHIBITORY COMPOUNDS ATTUNE PHARMACEUTICALS, INC. 2017-02-02 US disclosed
WO-2017001924-A1 THERAPEUTIC INHIBITORY COMPOUDS LIFESCI PHARMACEUTICALS, INC. (BB) 2017-01-05 WO disclosed
US-20160200704-A1 THERAPEUTIC INHIBITORY COMPOUNDS ATTUNE PHARMACEUTICALS, INC. 2016-07-14 US disclosed
WO-2016011209-A1 THERAPEUTIC INHIBITORY COMPOUNDS LIFESCI PHARMACEUTICALS, INC. (BB) 2016-01-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170029406-A1 THERAPEUTIC INHIBITORY COMPOUNDS KLKB1, SERPINB1, SERPINE1 KLKB1 1/4885MAP4K1 249/4885CHEK1 1372/4885
US-20170260163-A1 THERAPEUTIC INHIBITORY COMPOUNDS KLKB1, SERPINB1, SERPINE1 KLKB1 1/4885MAP4K1 249/4885CHEK1 1372/4885
US-20160200704-A1 THERAPEUTIC INHIBITORY COMPOUNDS KLKB1, SERPINB1, SERPINE1 KLKB1 1/4885MAP4K1 249/4885CHEK1 1372/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.